LinaTech Medical has been active in the field of radiation therapy for 30 years, having created a complete production chain from key components to finished devices. It is a high-tech enterprise integrating R&D, production, sales and service of radiotherapy equipment, holding more than 170 intellectual property rights. The company focuses on sustainable innovation in radiation therapy products, driving the iterative advancement of radiation therapy technologies. Its flagship product, the VenusX medical linear accelerator, has independent intellectual property rights in both China and the United States, and its core technologies are independently controlled. It received FDA approval in 2024.
LinaTech Medical has been deeply involved in the radiotherapy industry for 30 years, building a complete industrial chain from key components to finished machines. It is a high-tech enterprise integrating the R&D, production, sales, and service of radiotherapy equipment, with more than 170 intellectual property rights. The company focuses on sustainable innovation in radiotherapy products, promoting the iterative upgrade of radiotherapy technology. Its state-of-the-art product, the VenusX medical linear accelerator, holds independent intellectual property rights in both China and the United States, with core technology under independent control. In 2024, it received FDA approval.